MicroPort NeuroTech Limited (2172) AI Stock Analysis

• Market Cap: HK$7.66B
• Dividend Yield: 2.61%
• Average Volume (3M): 7.98M
• Price to Earnings (P/E): 27.5
• Beta (1Y): 0.94
• Revenue Growth: 12.48%
• EPS Growth: 71.75%
• Country: HK
• Employees: 527
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Devices
• EPS (TTM): 0.47
• Shares Outstanding: 584,595,600
• 10 Day Avg. Volume: 16,133,481
• 30 Day Avg. Volume: 7,977,443
• PEG Ratio: 2.39
• Price to Book (P/B): 7.12
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 59.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 78 Outperform
• Price Target: HK$14.00 ▲(14.19%Upside)

The company's strong financial performance with robust revenue and profit growth, coupled with positive technical indicators, drives the overall score. However, the moderate valuation and concerns about cash flow stability slightly temper the outlook. The absence of earnings call and corporate event data did not influence the score.

MicroPort NeuroTech Limited Business Overview & Revenue Model

Company Description

MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial arterial stent system to treat intracranial atherosclerotic disease; and Bridge, a rapamycin target eluting vertebral artery stent system to treat cerebral atherosclerotic stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

MicroPort NeuroTech Limited generates revenue primarily through the sale of its neurovascular products to healthcare providers, hospitals, and medical institutions. The company focuses on delivering advanced medical devices that address significant unmet needs in the treatment of neurovascular disorders. Key revenue streams include the sale of stents, coils, and other endovascular devices used in minimally invasive neurovascular procedures. Additionally, the company may engage in strategic partnerships and collaborations with other healthcare companies and research institutions to enhance its product offerings and expand its market reach, further contributing to its earnings.

MicroPort NeuroTech Limited Financial Statement Overview

Summary

MicroPort NeuroTech Limited exhibits strong revenue and profit growth, a solid balance sheet with low leverage, and efficient equity utilization. However, concerns about recent operational cash flow and cash generation capabilities need to be addressed to ensure ongoing liquidity.

Income Statement

MicroPort NeuroTech Limited has demonstrated robust revenue growth, with a notable increase from 2023 to 2024. The gross profit margin and net profit margin are strong, reflecting effective cost management and profitability. EBIT and EBITDA margins are also healthy, indicating operational efficiency and profitability. Overall, the income statement showcases a positive growth trajectory and solid profitability.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio, signifying low leverage and financial stability. The return on equity is impressive, suggesting efficient use of equity to generate profits. However, the equity ratio indicates a high reliance on equity, which could limit leverage benefits. Overall, the balance sheet reflects financial strength with controlled liabilities.

Cash Flow

The cash flow statement reveals some concerns with operational cash flow being zero in the latest period, which could indicate cash generation issues. The free cash flow has fluctuated in previous years, but there is a lack of data for current growth assessment. Despite past positive free cash flow, the current lack of free cash flow data poses a risk to cash flow stability. The overall cash flow position needs improvement to ensure ongoing liquidity.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
761.76M	665.62M	547.35M	382.80M	221.92M
	Gross Profit
555.93M	511.79M	393.00M	298.35M	164.78M
	EBIT
326.82M	219.82M	121.72M	84.73M	55.86M
	EBITDA
340.48M	221.60M	176.74M	108.83M	68.24M
	Net Income Common Stockholders
254.16M	145.55M	-21.77M	24.17M	45.29M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
995.06M	1.08B	1.13B	593.29M	425.49M
	Total Assets
2.04B	1.96B	1.82B	1.34B	785.61M
	Total Debt
37.12M	61.36M	85.24M	109.70M	331.15M
	Net Debt
-585.46M	-659.82M	-742.68M	-483.59M	-94.34M
	Total Liabilities
335.70M	322.39M	331.35M	1.52B	412.73M
	Stockholders Equity
1.71B	1.64B	1.47B	-174.94M	372.88M
Cash Flow		Free Cash Flow
227.79M	-48.83M	175.85M	99.43M	13.09M
	Operating Cash Flow
284.41M	153.78M	223.80M	157.41M	47.23M
	Investing Cash Flow
-160.55M	-233.16M	-344.52M	-186.79M	-73.04M
	Financing Cash Flow
-226.25M	-33.28M	329.54M	200.75M	431.88M

MicroPort NeuroTech Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 12.26
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2172, the sentiment is Positive. The current price of 12.26 is above the 20-day moving average (MA) of 11.31, above the 50-day MA of 10.79, and above the 200-day MA of 9.80, indicating a bullish trend. The MACD of 0.59 indicates Negative momentum. The RSI at 59.13 is Neutral, neither overbought nor oversold. The STOCH value of 79.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2172.

MicroPort NeuroTech Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2172	78 Outperform	HK$7.66B	27.53	15.22%	2.61%	12.48%	71.75%
Sector *	54 Neutral	$5.34B	3.27	-45.10%	3.30%	16.80%	0.02%
HUATF		$20.45B	7.53	9.25%	38.63%	―	―
WXIBF		$14.51B	28.26	8.17%	―	―	―
4WO		€478.01M	―	-10.43%	―	―	―
1612	69 Neutral	HK$303.80M	4.33	12.35%	7.31%	11.56%	20.29%
1877	59 Neutral	HK$35.82B	―	-19.78%	―	25.96%	39.58%

MicroPort NeuroTech Limited Corporate Events

MicroPort NeuroTech Announces 2025 Annual General Meeting Agenda

MicroPort NeuroTech Limited has announced its upcoming Annual General Meeting scheduled for June 27, 2025, in Shanghai. Key agenda items include the approval of financial statements for 2024, a proposed final dividend of HK$0.11 per share, and the re-election and election of independent non-executive directors. Additionally, the company seeks shareholder approval for a mandate allowing the buyback of up to 10% of its issued shares, reflecting its strategic focus on shareholder value and corporate governance.

MicroPort NeuroTech Engages in Strategic Wealth Management Subscription

MicroPort NeuroTech Limited announced that its subsidiary, MP NeuroTech Shanghai, has subscribed to a series of wealth management products with an aggregate outstanding principal amount of RMB240 million, using its cash surplus. This transaction, classified as a discloseable transaction under Hong Kong’s Listing Rules, is structured as a three-month deposit with SPD Bank, offering an expected annualized return rate ranging from 0.85% to 2.34%. The move is part of the company’s treasury management strategy and does not impact its working capital or operations, potentially enhancing its financial positioning without affecting its core business activities.

MicroPort NeuroTech Limited Grants Share Options to Boost Employee Engagement

MicroPort NeuroTech Limited has announced the granting of share options to 96 eligible participants, including three directors and 93 employees, allowing them to subscribe to a total of 2,445,000 ordinary shares. This initiative, part of the company’s Share Scheme, is designed to incentivize participants by giving them a personal stake in the company, thereby promoting business development and success. The options, which have a ten-year validity and a five-year vesting period, are not subject to performance targets but include a clawback mechanism to ensure alignment with company objectives.

MicroPort NeuroScientific Announces Final Dividend with Scrip Option

MicroPort NeuroScientific Corporation announced a final ordinary cash dividend of HKD 0.11 per share for the financial year ending December 31, 2024. Shareholders have the option to receive their dividends in cash or convert them into scrip shares, with further details on the scrip option to be announced. This announcement reflects the company’s commitment to returning value to its shareholders and may impact investor sentiment positively as it provides flexibility in dividend reception.

MicroPort NeuroTech Achieves Strong Financial Growth in 2024

MicroPort NeuroTech Limited reported a strong financial performance for the year ended December 31, 2024, with a 14.4% increase in revenue to RMB761.8 million and an 84.9% rise in net profit to RMB248.9 million. This growth was driven by breakthroughs in overseas markets, increased market share of cerebral atherosclerotic stenosis products, successful VBP bids for coil products, and the accelerated adoption of acute ischemic stroke products. The company also achieved a 44.2% increase in non-HKFRS adjusted net profit, leading to a recommended final dividend of HK$0.11 per share.